Showing 1 - 15 results of 15 for search 'Mark M. Awad', query time: 0.05s
Refine Results
-
1
-
2
-
3
Mechanistic patterns and clinical implications of oncogenic tyrosine kinase fusions in human cancers by Taek-Chin Cheong, Ahram Jang, Qi Wang, Giulia C. Leonardi, Biagio Ricciuti, Joao V. Alessi, Alessandro Di Federico, Mark M. Awad, Maria K. Lehtinen, Marian H. Harris, Roberto Chiarle
Published 2024-06-01
Article -
4
Additional impact of genetic ancestry over race/ethnicity to prevalence of KRAS mutations and allele-specific subtypes in non-small cell lung cancer by Xinan Wang, Kangcheng Hou, Biagio Ricciuti, Joao V. Alessi, Xihao Li, Federica Pecci, Rounak Dey, Jia Luo, Mark M. Awad, Alexander Gusev, Xihong Lin, Bruce E. Johnson, David C. Christiani
Published 2024-07-01
Article -
5
192 Clinicopathologic, genomic and immunophenotypic features and outcomes to immune checkpoint inhibitors in patients with mucinous lung adenocarcinoma by Mizuki Nishino, Biagio Ricciuti, Scott J Rodig, Joao V Alessi, Jia Luo, Mark M Awad, Bruce E Johnson, Federica Pecci, Alessandro Di Federico, Malini M Gandhi, Lynette M Sholl, Maisam Makarem, Emma Voligny, Tom Nguyen, Danielle Haradon
Published 2023-11-01Article -
6
Impact of TMB/PD-L1 expression and pneumonitis on chemoradiation and durvalumab response in stage III NSCLC by Joao V. Alessi, Biagio Ricciuti, Xinan Wang, Federica Pecci, Alessandro Di Federico, Giuseppe Lamberti, Arielle Elkrief, Scott J. Rodig, Emily S. Lebow, Jordan E. Eicholz, Maria Thor, Andreas Rimner, Adam J. Schoenfeld, Jamie E. Chaft, Bruce E. Johnson, Daniel R. Gomez, Mark M. Awad, Narek Shaverdian
Published 2023-07-01
Article -
7
Neoadjuvant atezolizumab + chemotherapy for resectable NSCLC: 3-year clinical update of phase II clinical trial results and translational findings by Benjamin Izar, Justin F Gainor, Mark M Awad, Codruta Chiuzan, Anjali Saqi, Catherine A Shu, Katja Schulze, Brian S Henick, Naiyer A Rizvi, Samyukta Mallick, Yohanna Georgis, Peter D Koch, Stephanie Izard, Robert F Garofano, Cheryl V Wong, Jessica Grindheim, Joshua R Sonett, Alison M Taylor
Published 2024-12-01
Article -
8
Multi-institutional analysis of aneuploidy and outcomes to chemoradiation and durvalumab in stage III non-small cell lung cancer by Biagio Ricciuti, Joao V Alessi, Mark M Awad, Arielle Elkrief, Jamie E Chaft, Bruce E Johnson, Xinan Wang, Allison L Richards, Federica Pecci, Alessandro Di Federico, Adam J Schoenfeld, Malini M Gandhi, Adam Price, Emily S Lebow, Patricia Mae G Santos, Maria Thor, Andreas Rimner, Daniel R Gomez, Narek Shaverdian
Published 2023-11-01
Article -
9
Efficacy of PD-(L)1 blockade monotherapy compared with PD-(L)1 blockade plus chemotherapy in first-line PD-L1-positive advanced lung adenocarcinomas: a cohort study by Yuan Chen, Biagio Ricciuti, Matthew D Hellmann, Hira Rizvi, Mark M Awad, Giuseppe Lamberti, Arielle Elkrief, Jamie E Chaft, Xinan Wang, Samantha Brown, Charles M Rudin, Joao M Victor Alessi, Isabel R Preeshagul, Federica Pecci, Alessandro Di Federico, Jacklynn V Egger, Gregory J Riely, Mark G Kris, Marc Ladanyi, Ronglai Shen, Adam J Schoenfeld
Published 2023-07-01
Article -
10
RAS-ON inhibition overcomes clinical resistance to KRAS G12C-OFF covalent blockade by Marie-Julie Nokin, Alessia Mira, Enrico Patrucco, Biagio Ricciuti, Sophie Cousin, Isabelle Soubeyran, Sonia San José, Serena Peirone, Livia Caizzi, Sandra Vietti Michelina, Aurelien Bourdon, Xinan Wang, Daniel Alvarez-Villanueva, María Martínez-Iniesta, August Vidal, Telmo Rodrigues, Carmen García-Macías, Mark M. Awad, Ernest Nadal, Alberto Villanueva, Antoine Italiano, Matteo Cereda, David Santamaría, Chiara Ambrogio
Published 2024-08-01
Article -
11
Prognostic effect of body mass index in patients with advanced NSCLC treated with chemoimmunotherapy combinations by James Artingstall, Alex Friedlaender, Alfredo Addeo, Judith Cave, Massimo Di Maio, Samuel Chan, Alessio Cortellini, Marcello Tiseo, Biagio Ricciuti, Francesco Facchinetti, Benjamin Besse, Joao V Alessi, Mark M Awad, David J Pinato, Giuseppe L Banna, Giuseppe Lamberti, Margarita Majem, Frank Aboubakar Nana, Charles Comins, Thomas Newsom-Davis, Victor R Vaz, Laura Mezquita, Davide Soldato, Filippo G Dall’Olio, Sethupathi Muthuramalingam, Aida Piedra, Elisa Andrini, Teresa Gorría, Delphine Hoton, Lacroix Valerie, Andrea Caglio, Hayley McKenzie, Joanne S Evans, Antonio D'Alessio, Claudia A M Fulgenzi
Published 2022-02-01
Article -
12
Patient-Reported Health-Related Quality of Life in KEYNOTE-604: Pembrolizumab or Placebo Added to Etoposide and Platinum as First-Line Therapy for Extensive-Stage SCLC by Hye Ryun Kim, MD, PhD, Mark M. Awad, MD, PhD, Alejandro Navarro, MD, Maya Gottfried, MD, Solange Peters, MD, PhD, Tibor Csőszi, MD, Parneet K. Cheema, MD, Delvys Rodriguez-Abreu, MD, PhD, Mirjana Wollner, MD, James Chih-Hsin Yang, MD, PhD, Julien Mazieres, MD, PhD, Francisco J. Orlandi, MD, Alexander Luft, MD, PhD, Mahmut Gümüş, MD, Terufumi Kato, MD, Gregory P. Kalemkerian, MD, Yiwen Luo, PhD, Melissa L. Santorelli, PhD, MPH, M. Catherine Pietanza, MD, Charles M. Rudin, MD, PhD
Published 2023-11-01
Article -
13
218 Prospective spatial immune cell profiling identifies features of the tumor-immune microenvironment associated with genomic alterations and patient survival in a 2,023 patient p... by Sara M Tolaney, James Lindsay, Michael Manos, Biagio Ricciuti, Anita Giobbie-Hurder, Scott J Rodig, Joao V Alessi, Mark M Awad, Sandro Santagata, Bruce E Johnson, Glenn J Hanna, Elio Adib, Jason Weirather, Xinan Wang, Bijaya Sharma, Kathleen Pfaff, Kristen D Felt, William Lotter, Panagiotis Konstantinopoulos, Madison Turner, Federica Pecci, Emma L Welsh, Stephanie M Jones, Jennifer O Altreuter, Ian D Dryg, Alessandro Di Federico, Malini M Gandhi, Sabrina J Chan, Marta Holovatska, Melissa E Hughes, O’Meara Tess A, Neal I Lindeman, Jennifer Curtis, Peter K Sorger, Ethan Cerami, Lynette M Sholl, Jonathan A Novak
Published 2023-11-01Article -
14
Brief Report: Clinical Characteristics and Outcomes of Patients With Thoracic SMARCA4-Deficient Undifferentiated Tumors by Alissa J. Cooper, MD, Andrea Arfe, PhD, Biagio Ricciuti, MD, Andréanne Gagné, MD, PhD, Lynette M. Sholl, MD, Alessandro Di Federico, MD, Mark M. Awad, MD, PhD, Mihaela Aldea, MD, PhD, Maria Rosa Ghigna, MD, Miruna Grecea, MD, Phoebe Clark, MS, Jamie E. Chaft, MD, Mark G. Kris, MD, Gregory J. Riely, MD, Charles M. Rudin, MD, PhD, Ibiayi Dagogo-Jack, MD, Mari Mino-Kenudson, MD, Lingzhi Hong, MD, PhD, Neda Kalhor, MD, Natalie Vokes, MD, Anita Bowman, MS, Soo-Ryum Yang, MD, Natasha Rekhtman, MD, PhD, Adam J. Schoenfeld, MD
Published 2025-01-01
Article -
15
Three-Year Overall Survival Outcomes and Correlative Analyses in Patients With NSCLC and High (50%–89%) Versus Very High (≥90%) Programmed Death-Ligand 1 Expression Treated With Fi... by Biagio Ricciuti, MD, PhD, Arielle Elkrief, MD, Jessica Lin, MD, Jianjun Zhang, MD, Joao V. Alessi, MD, Giuseppe Lamberti, MD, PhD, Malini Gandhi, MD, Alessandro Di Federico, MD, Federica Pecci, MD, Xinan Wang, PhD, Maisam Makarem, MD, PhD, Cassio Murilo Hidalgo Filho, MD, Teresa Gorria, MD, Arushi Saini, BS, Cindy Pabon, MD, James Lindsay, PhD, Kathleen L. Pfaff, PhD, Emma L. Welsh, BS, Mizuki Nishino, MD, Lynette M. Sholl, MD, Scott Rodig, MD, Saadettin Kilickap, MD, Petra Rietschel, MD, Debra AG. McIntyre, PhD, Jean-Francois Pouliot, MD, Mehmet Altan, MD, Justin F. Gainor, MD, John V. Heymach, MD, Adam J. Schoenfeld, MD, Mark M. Awad, MD, PhD
Published 2024-09-01
Article